Altimmune Inc (ALT)
8.68
+0.28
(+3.27%)
USD |
NASDAQ |
Nov 22, 16:00
8.65
-0.03
(-0.35%)
After-Hours: 20:00
Altimmune Cash from Operations (Quarterly): -27.12M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -27.12M |
June 30, 2024 | -18.11M |
March 31, 2024 | -16.36M |
December 31, 2023 | -16.53M |
September 30, 2023 | -20.49M |
June 30, 2023 | -19.38M |
March 31, 2023 | -19.41M |
December 31, 2022 | -17.31M |
September 30, 2022 | -15.05M |
June 30, 2022 | -16.70M |
March 31, 2022 | -13.53M |
December 31, 2021 | -21.97M |
September 30, 2021 | -17.78M |
June 30, 2021 | -18.93M |
March 31, 2021 | -19.57M |
December 31, 2020 | -13.28M |
September 30, 2020 | -9.505M |
June 30, 2020 | -7.171M |
March 31, 2020 | -4.347M |
December 31, 2019 | -2.002M |
September 30, 2019 | -2.427M |
June 30, 2019 | -3.060M |
March 31, 2019 | -2.113M |
December 31, 2018 | -5.155M |
September 30, 2018 | -1.023M |
Date | Value |
---|---|
June 30, 2018 | 0.3481M |
March 31, 2018 | -3.559M |
December 31, 2017 | -4.806M |
September 30, 2017 | -4.259M |
June 30, 2017 | -7.806M |
March 31, 2017 | -3.343M |
December 31, 2016 | -1.493M |
September 30, 2016 | -1.893M |
June 30, 2016 | -1.612M |
March 31, 2016 | -1.355M |
December 31, 2015 | -1.829M |
September 30, 2015 | -1.327M |
June 30, 2015 | 2.653M |
March 31, 2015 | -2.713M |
December 31, 2014 | -3.522M |
September 30, 2014 | -2.124M |
June 30, 2014 | -0.5333M |
March 31, 2014 | -2.294M |
December 31, 2013 | -6.256M |
September 30, 2013 | -0.6767M |
June 30, 2013 | -0.4954M |
March 31, 2013 | 0.2604M |
December 31, 2012 | -2.145M |
September 30, 2012 | 1.734M |
June 30, 2012 | -2.704M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-27.12M
Minimum
Sep 2024
-2.002M
Maximum
Dec 2019
-15.73M
Average
-17.00M
Median
Cash from Operations (Quarterly) Benchmarks
Eli Lilly and Co | 3.712B |
Viking Therapeutics Inc | -21.96M |
Amgen Inc | 3.571B |
Avid Bioservices Inc | -3.68M |
NovaBay Pharmaceuticals Inc | -2.061M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | 1.199M |
Cash from Financing (Quarterly) | 0.266M |
Free Cash Flow | -78.12M |
Free Cash Flow Per Share (Quarterly) | -0.3815 |
Free Cash Flow to Equity (Quarterly) | -27.12M |
Free Cash Flow Yield | -13.27% |